VER Share PerformanceMore
|52 week high||65.000 01/03/16|
|52 week low||25.000 24/02/17|
|52 week change||-29.250 (-53.18%)|
|4 week volume||11,610,571 30/01/17|
Latest News« previous» nextMore
21/02/2017 - 07:00 RNS
RNS Number: 3708X Vernalis PLC 21 February 2017 21 February 2017 Vernalis plc Unaudited Interim Results for the six months ended 31 December 2016 Tuzistra XR prescriptions growing steadily as 2016/2017 US cough cold season progresses Two further NDAs from cough cold franchise accepted for review by FDA with potential approvals later this year Vernalis...
14/02/2017 - 11:10 StockMarketWire
Stifel today reaffirms its buy investment rating on Vernalis PLC (LON:VER) and set its price target at 104p.
14/02/2017 - 07:00 RNS
RNS Number: 7745W Vernalis PLC 14 February 2017 14 February 2017 LSE: VER Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis. In Februa...
30/01/2017 - 13:03 StockMarketWire
Vernalis will announce its unaudited interim results for the six months ended 31 December on 21 February. At 1:03pm: (LO...
30/01/2017 - 12:36 RNS
RNS Number: 4717V Vernalis PLC 30 January 2017 30 January 2017 Vernalis plc ("Vernalis" or the "Company") Notice of Results for the Six Months Ended 31 December 2016 Vernalis plc (LSE: VER) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017. The results announcement will ...
25/01/2017 - 11:30 StockMarketWire
Neill Ricketts, CEO of Versarien (VRS) (LSE:VRS) will give a presentation at the Shares Spotlight Evening on 9 February 2...
21/12/2016 - 07:23 StockMarketWire
Vernalis and Tris Pharma Inc announce that the US Food and Drug Administration (FDA) has accepted the CCP-08 New ...
21/12/2016 - 07:00 RNS
RNS Number: 4179S Vernalis PLC 21 December 2016 21 December 2016 LSE: VER FDA accepts CCP-08 NDA for full review PDUFA date of 4 August 2017 Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-08 New Drug Application ("NDA") for full review. This triggers a m...
|Dividend yield||0 %|
Equity Research (VER)
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...
Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from its extended release (ER) prescription only (...
The issue of 80m new shares at 50p/share has raised £40m (gross), which enables Vernalis to focus on executing its operational plan and removes uncertainty over whether it is sufficiently funded...
- 1 of 3
Latest discussion posts More
“Just me and him then, anyone else? M”▼
“Wow these guys really believe this is a winner. Glad I bought in last week. M”▼
“Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754 "Vernalis intends to raise #40m (gross) through the issue of ...”▼
Codes & Symbols
|Symbols||VER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER|